ATE156018T1 - Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose - Google Patents

Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose

Info

Publication number
ATE156018T1
ATE156018T1 AT90909874T AT90909874T ATE156018T1 AT E156018 T1 ATE156018 T1 AT E156018T1 AT 90909874 T AT90909874 T AT 90909874T AT 90909874 T AT90909874 T AT 90909874T AT E156018 T1 ATE156018 T1 AT E156018T1
Authority
AT
Austria
Prior art keywords
igf2
igf1
medication
producing
treatment
Prior art date
Application number
AT90909874T
Other languages
English (en)
Inventor
Michael E Lewis
James C Kauer
Kevih R Smith
Kathleen V Callison
Frank Baldino Jr
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE156018T1 publication Critical patent/ATE156018T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT90909874T 1989-06-05 1990-06-05 Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose ATE156018T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/361,595 US5093317A (en) 1989-06-05 1989-06-05 Treating disorders by application of insulin-like growth factor

Publications (1)

Publication Number Publication Date
ATE156018T1 true ATE156018T1 (de) 1997-08-15

Family

ID=23422661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909874T ATE156018T1 (de) 1989-06-05 1990-06-05 Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose

Country Status (9)

Country Link
US (1) US5093317A (de)
EP (2) EP0798000A3 (de)
JP (1) JPH0768138B2 (de)
AT (1) ATE156018T1 (de)
CA (1) CA2058443C (de)
DE (1) DE69031168T2 (de)
DK (1) DK0476044T3 (de)
ES (1) ES2106735T3 (de)
WO (1) WO1990014838A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5792831A (en) * 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
US5831001A (en) * 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
US5674849A (en) * 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
SE9101341D0 (sv) * 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
DE69218948T2 (de) * 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5925564A (en) * 1991-11-06 1999-07-20 Baylor College Of Medicine Expression vector systems and method of use
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US6204240B1 (en) * 1991-11-22 2001-03-20 Genentech, Inc. TGF-β1 to improve neural outcome
WO1993010806A1 (en) * 1991-11-25 1993-06-10 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
US5281582A (en) * 1992-02-27 1994-01-25 Alliance Pharmaceuticals, Corp. Serum growth factor
AU4238493A (en) * 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
NZ253867A (en) * 1992-06-12 1996-08-27 Cephalon Inc Treating peripheral neuropathy using igf-1 or igf-3
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
CA2155540A1 (en) * 1993-02-08 1994-08-18 Frank Collins Methods for treating amyotrophic lateral sclerosis with cntf
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
AU1439095A (en) * 1993-12-15 1995-07-03 Thomas Jefferson University Igf-1 analogs
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5650496A (en) 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
US6756484B1 (en) 1995-04-14 2004-06-29 Cephalon, Inc. IGF-I purification process
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0766966A3 (de) * 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
WO1997011959A1 (en) * 1995-09-29 1997-04-03 Receptron, Inc. Biologically active mhc peptides having a repeated amino acid sequence motif
CA2240327C (en) * 1995-12-13 2005-07-12 Aurogen Incorporated Method for effecting changes in the central nervous system by administration of igf-i or igf-ii
US5798715A (en) * 1996-06-28 1998-08-25 Saperstone; Dorothy Luhr Method and device for accessing remote control functions
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US20030069177A1 (en) * 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
JP2002513416A (ja) 1997-05-22 2002-05-08 セファロン・インコーポレイテッド ビタミンｄアナログおよびそれらのニューロン効果
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
US6358916B1 (en) * 1998-07-22 2002-03-19 Thomas T. Chen Biological activity of IGF-I E domain peptide
US7118752B2 (en) * 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
US7700353B2 (en) * 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
KR20010072354A (ko) * 1998-08-11 2001-07-31 다께우찌 마사야쓰 혈당치 조절제
CA2356109C (en) * 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
EP1982732A3 (de) 2000-02-11 2011-06-08 Bayer HealthCare LLC Faktor VII- oder VIIA-ähnliche Konjugate
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2001288443B2 (en) * 2000-08-29 2007-06-07 Aurogen Inc. Method for treating the central nervous system by administration of IGF structural analogs
US20020082215A1 (en) * 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US7700733B2 (en) * 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
EP1549677B1 (de) * 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII- ODER FVIIa-VARIANTEN MIT ERHÖHTER KOAGULATIONSWIRKUNG
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
DK2085470T3 (da) * 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
EP1791551B1 (de) * 2004-08-30 2020-02-26 Ipsen Biopharmaceuticals, Inc. Verfahren und vorrichtung zur diagnose und behandlung von mangelstörung an insulinähnlichem wachstumsfaktor
US20060069008A1 (en) * 2004-09-28 2006-03-30 Sanjay Mistry Treatment of neurological deficits in the striatum or substanta nigra pars compacta
US20060069009A1 (en) * 2004-09-28 2006-03-30 Messina Darin J Treatment of neurological deficits in the striatum or substanta nigra pars compacta
US20090012499A1 (en) * 2005-02-08 2009-01-08 Japan As Rep. By Pres. Of Nat. Cardiovascular Ctr. Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
ES2322685B2 (es) * 2006-11-21 2010-03-15 Universidad De Malaga Utilizacion de dosis bajas de igf-ii en el envejecimiento por sus efectos neuroprotectores y hepatoprotectores.
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
AU2009231394B2 (en) * 2008-04-03 2013-09-05 F. Hoffmann-La Roche Ag Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders
TWI541020B (zh) 2008-04-17 2016-07-11 巴克斯歐塔公司 生物活性胜肽
JP6983069B2 (ja) 2014-10-20 2021-12-17 ニューラルステム， インコーポレイテッド 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法
WO2016184427A1 (zh) * 2015-05-21 2016-11-24 中国科学院上海生命科学研究院 低氧处理的间充质干细胞及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341762A (en) * 1981-04-07 1982-07-27 Haast William E Use of snake venoms for treatment of neurological and related disorders
JPS5965058A (ja) * 1982-10-05 1984-04-13 Daiichi Rajio Isotope Kenkyusho:Kk ヘンエイコサペプチド
US4699875A (en) * 1982-11-24 1987-10-13 Baylor College Of Medicine Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors
US4511390A (en) * 1983-06-10 1985-04-16 E. I. Du Pont De Nemours And Company Aralkylcarbamoyl peptide alcohols
WO1988001693A1 (en) * 1986-09-05 1988-03-10 Young Niels O Magnet ball pump
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
SE8505920D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4751645A (en) * 1986-08-12 1988-06-14 Abrams William R Method for sonic analysis of an anomaly in a seafloor topographic representation
GB8624560D0 (en) * 1986-10-14 1986-11-19 Bp Chem Int Ltd Polymer polyols
JPS63196524A (ja) * 1987-02-10 1988-08-15 Wakunaga Pharmaceut Co Ltd 経粘膜吸収型制ガン作用調節剤
DE3851776T2 (de) * 1987-04-28 1995-05-04 Boehringer Mannheim Gmbh Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
CA1338337C (en) * 1988-09-27 1996-05-21 Health Foundation Limited (The) Method and composition for the treatment of burns
WO1991002067A1 (en) * 1989-07-27 1991-02-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation of nerve growth factor synthesis in the central nervous system

Also Published As

Publication number Publication date
US5093317A (en) 1992-03-03
EP0476044B1 (de) 1997-07-30
DE69031168T2 (de) 1997-12-04
DK0476044T3 (da) 1997-11-17
HK1010989A1 (en) 1999-07-02
DE69031168D1 (de) 1997-09-04
CA2058443A1 (en) 1990-12-06
EP0798000A3 (de) 1998-01-14
EP0798000A2 (de) 1997-10-01
EP0476044A4 (en) 1992-07-01
ES2106735T3 (es) 1997-11-16
WO1990014838A1 (en) 1990-12-13
JPH0768138B2 (ja) 1995-07-26
JPH04507240A (ja) 1992-12-17
EP0476044A1 (de) 1992-03-25
CA2058443C (en) 1998-11-03

Similar Documents

Publication Publication Date Title
DE69031168D1 (de) Verwendung von IGF1 oder IGF2 zur Herstellung eines Medikaments für die Behandlung von amyotrophischen Lateralsklerose
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69524679D1 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE69433820D1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ATE459335T1 (de) Verfahren zur behandlung von augenerkrankungen
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE3855525D1 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
DE69218948D1 (de) IGF-I zur Verbesserung der neuronale Lage
DE69218255D1 (de) Verwendung von amino-2-trifluormethoxy-6-benzothiazol (riluzol) zur herstellung eines medikamentes zur behandlung von erkrankungen des motoneurons
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
AU1808488A (en) Compounds for the treatment of alzheimer's disease
ATE127342T1 (de) Verwendung von modafinil zur herstellung eines antiischämischen arzneimittels.
DE69121561D1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69229944D1 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
IT1222395B (it) Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ZA947783B (en) Method of treating depressed reticuloendothelial system function
EP0515434A4 (en) Method for treating intestinal diseases
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
RU94011321A (ru) Способ профилактики и лечения заболеваний кожи
GR3022706T3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time